SI-BONE (NASDAQ:SIBN) Releases Earnings Results, Beats Estimates By $0.03 EPS


Share on StockTwits

SI-BONE (NASDAQ:SIBN) posted its earnings results on Sunday. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.03, MarketWatch Earnings reports. SI-BONE had a negative net margin of 61.67% and a negative return on equity of 45.03%.

NASDAQ SIBN traded down $2.96 on Tuesday, hitting $33.00. 523,542 shares of the stock were exchanged, compared to its average volume of 290,663. SI-BONE has a 52-week low of $14.37 and a 52-week high of $37.21. The firm has a market capitalization of $1.08 billion, a P/E ratio of -20.62 and a beta of 1.41. The stock has a fifty day moving average price of $33.19 and a two-hundred day moving average price of $28.84. The company has a debt-to-equity ratio of 0.39, a quick ratio of 12.22 and a current ratio of 12.65.

A number of research analysts recently weighed in on the stock. Morgan Stanley raised their target price on shares of SI-BONE from $38.00 to $41.00 and gave the company an “overweight” rating in a report on Tuesday. Truist Securities raised their target price on shares of SI-BONE from $35.00 to $43.00 in a report on Tuesday. Truist lifted their price objective on shares of SI-BONE from $35.00 to $43.00 in a research note on Tuesday. Canaccord Genuity lifted their price objective on shares of SI-BONE from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, JMP Securities lifted their price objective on shares of SI-BONE from $27.00 to $35.00 and gave the stock an “outperform” rating in a research note on Friday, January 8th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $36.63.

In other news, CEO Jeffrey W. Dunn sold 2,112 shares of SI-BONE stock in a transaction on Friday, April 16th. The stock was sold at an average price of $33.65, for a total transaction of $71,068.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Laura Francis sold 18,358 shares of SI-BONE stock in a transaction on Thursday, March 18th. The stock was sold at an average price of $33.34, for a total value of $612,055.72. Following the sale, the chief financial officer now owns 197,471 shares of the company’s stock, valued at $6,583,683.14. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,067,472 shares of company stock valued at $32,658,438. Corporate insiders own 15.50% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

Featured Story: The components of the Stochastic Momentum Index

Earnings History for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.